About Helus Pharma Inc. Common Stock (HELP)

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety.

Primary exchange (MIC)XNAS
Listed since2020-11-10
Market capitalization$612.2 million
Shares outstanding79,817,163
Employees50
HeadquartersUS
Websitewww.helus.com

HELP trading today

HELP has traded between $7.03 and $8.07 in the current session, a range of $1.04. The latest price of $7.39 sits in the middle of that range (34% of the way from low to high). It opened at $8.07, a gap up of 5.22% from the prior close of $7.67. The volume-weighted average price is $7.44, and the stock is trading below it. Traders often use VWAP as a gauge of whether buyers or sellers have had the better average entry today.

Open$8.07
High$8.07
Low$7.03
Previous close$7.67
Volume1,522,065
VWAP$7.44

Where HELP holders stand

StockMarketLoop's Market Position model estimates how the shares traded between 2026-08-19 and 2026-11-17 were bought. Its estimate of the average cost basis is $10.22; at $7.39 the stock trades 27.7% below that level. About 6.1% of those shares are estimated to be held at a profit at the current price. A low figure means most recent buyers are underwater, so rallies can meet selling from holders trying to get back to break even. The densest nearby clusters of cost basis sit around $6.97 (support) and $8.76 (resistance). Roughly 70% of the estimated cost basis lies between $8.14 and $12.68, and 90% between $7.31 and $13.64.

This is a model estimate built from price and volume history, not a record of actual positions.

How to read this page

Quote figures come from StockMarketLoop's market data feed and may be delayed; the timestamp in the summary above shows when they were observed. Company details come from public reference data. The cost-basis section is a statistical model, not a forecast. Nothing here is investment advice; see our financial disclaimer and editorial policy.

HELP: Helus Pharma Inc. Common Stock

Company identity verified 2026-11-17. Current quotes, news, filings and options load in the terminal; unavailable data is left unavailable.